Emerging Antibiotic Resistance Patterns Affect Visual Outcome Treating Acute Endophthalmitis.

antibiotic resistance corticosteroids endophthalmitis moxifloxacin vancomycin

Journal

Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404

Informations de publication

Date de publication:
23 Jun 2022
Historique:
received: 25 04 2022
revised: 08 06 2022
accepted: 10 06 2022
entrez: 27 7 2022
pubmed: 28 7 2022
medline: 28 7 2022
Statut: epublish

Résumé

Background: Examining the effect of antibiotic resistance, use of intravitreal antibiotics and systemic corticosteroids on visual outcome of eyes with acute endophthalmitis. Methods: We included 226 eyes with acute endophthalmitis, treated using a standardized protocol. Visual outcome up to 12 months was assessed related to biopsy results, antibiotics resistance and treatment regimens. Results: Vitreous biopsies were more likely to be culture-positive (41.1%) than anterior chamber biopsies (21.6%, p < 0.0001). Antibiotic resistance for amikacin was found in 19 eyes (24.7%), vancomycin in 29 eyes (31.5%) and moxiflocacin in 14 eyes (16.1%). At presentation 91.53% of eyes had BCVA < 20/40, reducing by 1 month to 69.94% (p < 0.0001) and remaining stable at 12 months. There was no difference in visual outcome for those receiving early systemic corticosteroids. Endophthalmitis following cataract surgery (OR 1.66, 1.04−2.66 95% CI, p = 0.03) and receiving intravitreal vancomycin (OR 3.15, 1.18−8.42 95% CI, p = 0.02) were associated with a greater chance of final BCVA ≥ 20/40. Conclusion: Using vitreous taps with intravitreal antibiotics, despite an increase in resistance to both vancomycin and moxifloxacin, results in a final BCVA > 20/200 in half of eyes and ≥20/40 in a third. Early treatment with intravitreal antibiotics should not be delayed.

Identifiants

pubmed: 35884097
pii: antibiotics11070843
doi: 10.3390/antibiotics11070843
pmc: PMC9311540
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Mediators Inflamm. 2012;2012:196094
pubmed: 22973073
Surv Ophthalmol. 2018 Sep - Oct;63(5):677-693
pubmed: 29453989
Acta Ophthalmol. 2012 Nov;90(7):e572-3
pubmed: 22429465
J Ophthalmic Inflamm Infect. 2020 Feb 27;10(1):9
pubmed: 32103368
Curr Opin Ophthalmol. 2021 Jan;32(1):62-68
pubmed: 33196543
Ophthalmol Retina. 2018 Sep;2(9):979-980
pubmed: 31047231
Arch Ophthalmol. 1995 Dec;113(12):1479-96
pubmed: 7487614
Surv Ophthalmol. 1997 Mar-Apr;41(5):395-401
pubmed: 9163836
Ophthalmology. 2020 Feb;127(2):151-158
pubmed: 31611015
Br J Ophthalmol. 2016 Apr;100(4):446-52
pubmed: 26701686
Clin Exp Ophthalmol. 2020 Aug;48(6):813-820
pubmed: 32348002
Arch Ophthalmol. 2006 Feb;124(2):178-82
pubmed: 16476886
Surv Ophthalmol. 1998 Nov-Dec;43(3):193-224
pubmed: 9862309
Int Ophthalmol. 2020 Jan;40(1):73-79
pubmed: 31414274
J Glob Antimicrob Resist. 2022 Jun;29:236-240
pubmed: 35339737
Ophthalmol Retina. 2020 Nov;4(11):1103-1108
pubmed: 32387316
J Cataract Refract Surg. 2008 Sep;34(9):1439-50
pubmed: 18721702
JAMA Ophthalmol. 2017 Jul 1;135(7):814-815
pubmed: 28617914
J Ophthalmic Inflamm Infect. 2013 Apr 22;3(1):46
pubmed: 23607574
Retina. 2008 Mar;28(3):473-6
pubmed: 18327141
Am J Ophthalmol Case Rep. 2018 Dec 08;13:127-130
pubmed: 30662972
Br J Ophthalmol. 2007 Oct;91(10):1350-3
pubmed: 17389745
Ophthalmology. 2018 Aug;125(8):1279-1286
pubmed: 29477689
Int J Retina Vitreous. 2021 Feb 16;7(1):14
pubmed: 33593443
Am J Ophthalmol. 2007 Feb;143(2):338-40
pubmed: 17258525
Ophthalmology. 2005 Jul;112(7):1199-206
pubmed: 15921759
Ophthalmology. 2014 Dec;121(12):2387-92
pubmed: 25178807
Am J Ophthalmol Case Rep. 2018 Feb 28;10:211-214
pubmed: 29552670
Clin Microbiol Infect. 2015 Jun;21(6):592.e1-8
pubmed: 25680315

Auteurs

Xia-Ni Wu (XN)

NIHR Biomedical Research Centre, Moorfields Eye Hospital, London EC1V 2PD, UK.
Institute of Ophthalmology, University College London, London EC1V 9EL, UK.

Yi-Hsing Chen (YH)

NIHR Biomedical Research Centre, Moorfields Eye Hospital, London EC1V 2PD, UK.
Institute of Ophthalmology, University College London, London EC1V 9EL, UK.
Department of Ophthalmology, Chang Gung Memorial Hospital, Taoyuan 10507, Taiwan.

Lazha Sharief (L)

NIHR Biomedical Research Centre, Moorfields Eye Hospital, London EC1V 2PD, UK.
Institute of Ophthalmology, University College London, London EC1V 9EL, UK.

Ahmed Al-Janabi (A)

NIHR Biomedical Research Centre, Moorfields Eye Hospital, London EC1V 2PD, UK.
Institute of Ophthalmology, University College London, London EC1V 9EL, UK.

Nura Al Qassimi (N)

NIHR Biomedical Research Centre, Moorfields Eye Hospital, London EC1V 2PD, UK.

Sue Lightman (S)

NIHR Biomedical Research Centre, Moorfields Eye Hospital, London EC1V 2PD, UK.
Institute of Ophthalmology, University College London, London EC1V 9EL, UK.

Oren Tomkins-Netzer (O)

NIHR Biomedical Research Centre, Moorfields Eye Hospital, London EC1V 2PD, UK.
Institute of Ophthalmology, University College London, London EC1V 9EL, UK.
Department of Ophthalmology, Lady Davis Carmel Medical Center, Ruth and Bruch Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa 3200003, Israel.

Classifications MeSH